- Conditions
- Myositis, Dermatomyositis
- Interventions
- Deucravacitinb
- Drug
- Lead sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- NIH
- Eligibility
- 18 Years to 90 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–29
of 5
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Dermatomyositis
- Interventions
- IMO-8400 Dose Group 1, IMO-8400 Dose Group 2, Placebo
- Drug
- Lead sponsor
- Idera Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Irvine, California + 14 more
- Conditions
- Systemic Lupus Erythematosus (With and Without Nephritis), Idiopathic Inflammatory Myopathy, Systemic Sclerosis
- Interventions
- ALLO-329, Cyclophosphamide, Fludarabine
- Genetic · Drug
- Lead sponsor
- Allogene Therapeutics
- Industry
- Eligibility
- 18 Years to 69 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Loma Linda, California • Aurora, Colorado + 10 more
- Conditions
- Dermatomyositis
- Interventions
- human immunoglobulin G, Placebo
- Drug
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 134 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 15
- States / cities
- Glendale, Arizona • Phoenix, Arizona • Los Angeles, California + 12 more
- Conditions
- Dermatomyositis
- Interventions
- Brepocitinib, Placebo
- Drug
- Lead sponsor
- Priovant Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 241 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 39
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Irvine, California + 33 more